Holen Sie sich die Stockscreener-App
39.19
1.03%
0.40
Schlusskurs vom Vortag:
$38.79
Offen:
$39.2
24-Stunden-Volumen:
729.91K
Relative Volume:
0.81
Marktkapitalisierung:
$2.79B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-141.43M
KGV:
-15.94
EPS:
-2.4581
Netto-Cashflow:
$-226.41M
1W Leistung:
+1.29%
1M Leistung:
-15.72%
6M Leistung:
+14.19%
1J Leistung:
+58.99%
1-Tages-Spanne:
$38.70
$40.38
1-Wochen-Bereich:
$35.78
$40.38
52-Wochen-Spanne:
$15.80
$94.90
Structure Therapeutics Inc Adr Stock (GPCR) Company Profile
Firmenname
Structure Therapeutics Inc Adr
Sektor
Branche
Telefon
(650) 457-1978
Adresse
601 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO
Compare GPCR vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GPCR
Structure Therapeutics Inc Adr
|
39.19 | 2.76B | 0 | -141.43M | -226.41M | -2.4581 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Structure Therapeutics Inc Adr Stock (GPCR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-27 | Eingeleitet | Canaccord Genuity | Buy |
| 2026-03-26 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-05-02 | Eingeleitet | Citigroup | Buy |
| 2025-02-28 | Eingeleitet | William Blair | Outperform |
| 2025-01-08 | Eingeleitet | Stifel | Buy |
| 2024-12-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-09-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-05-21 | Eingeleitet | JP Morgan | Overweight |
| 2024-04-09 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-19 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-07-27 | Eingeleitet | Piper Sandler | Overweight |
| 2023-05-25 | Fortgesetzt | Jefferies | Buy |
| 2023-02-28 | Eingeleitet | BMO Capital Markets | Outperform |
| 2023-02-28 | Eingeleitet | Guggenheim | Buy |
| 2023-02-28 | Eingeleitet | Jefferies | Buy |
| 2023-02-28 | Eingeleitet | SVB Securities | Outperform |
Alle ansehen
Structure Therapeutics Inc Adr Aktie (GPCR) Neueste Nachrichten
Structure Therapeutics Stock Is Up 47%, but One Fund Just Fully Exited a $2.6 Million Position - AOL.com
This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 Million - Yahoo Finance
Why (GPCR) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Why Structure Therapeutics Shares Are Sinking Today - TipRanks
Monashee Reduces Stake in Structure Therapeutics Amid Competitive Landscape - Intellectia AI
Monashee Scales Back Its Bet on Structure Therapeutics - Yahoo Finance
HighVista Strategies Sells 69,092 Shares of Structure Therapeutics in Q1 2026News and Statistics - IndexBox
This Obesity Drug Stock Has Jumped 60% as Phase 3 Plans Advance. A Fund Just Sold $4.7 Million - The Globe and Mail
This Obesity Drug Stock Has Jumped 60% as Phase 3 Plans Advance. A Fund Just Sold $4.7 Million - The Motley Fool
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Can Novo Nordisk Sustain Its GLP-1 Edge Amid Lilly's Growing Pressure? - TradingView
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Ibio (IBIO), MaxCyte (MXCT) and Atea Pharmaceuticals (AVIR) - The Globe and Mail
Understanding Momentum Shifts in (GPCR) - Stock Traders Daily
Analysts Offer Insights on Healthcare Companies: BioAge Labs, Inc. (BIOA) and Lexeo Therapeutics, Inc. (LXEO) - The Globe and Mail
Brokers Offer Predictions for GPCR Q1 Earnings - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Announces Quarterly Earnings Results, Beats Expectations By $0.04 EPS - MarketBeat
GPCR Structure posts massive EPS miss as losses widen; stock barely flinches, down 0.13%.Product Revenue - Newser
Structure Therapeutics ADA Data Could Reframe Oral Obesity And Diabetes Prospects - Sahm
Structure Therapeutics Reports 16% Weight Loss With Oral GLP-1RA Aleniglipron in Phase 2, Prepares for Phase 3 Obesity Trial and ADA 2026 Data Presentations - Minichart
Structure Therapeutics Expands ATM Capacity, Advances Obesity Program - TipRanks
Structure Therapeutics : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
Structure Therapeutics (NASDAQ: GPCR) funds obesity drug push with $1.46B cash - Stock Titan
Obesity drug gains momentum as Structure (NASDAQ: GPCR) eyes Phase 3, boosts ATM - Stock Titan
Obesity pill developer posts 16.3% weight loss, targets Phase 3 - Stock Titan
GPCR (NASDAQ: GPCR) expands ATM program to $400M capacity - Stock Titan
Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NVO), OnKure Therapeutics (OKUR) and Cogent Biosciences (COGT) - The Globe and Mail
Analysts Are Bullish on Top Healthcare Stocks: CG Oncology, Inc. (CGON), Evolus (EOLS) - The Globe and Mail
Novo Nordisk Before Q1 Earnings: How Should Investors Play the Stock? - TradingView
Structure Therapeutics (GPCR) Is Down 7.2% After Strong Phase 2 Oral GLP‑1 Obesity Data – Has The Bull Case Changed? - Sahm
Avoiding Lag: Real-Time Signals in (GPCR) Movement - Stock Traders Daily
Structure Therapeutics (NASDAQ:GPCR) Shares Gap UpShould You Buy? - MarketBeat
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Crispr Therapeutics AG (CRSP) - The Globe and Mail
Why Structure Therapeutics Shares Are Suddenly Sinking - TipRanks
Structure Therapeutics (GPCR) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Analysts Offer Insights on Healthcare Companies: Rocket Pharmaceuticals (RCKT) and TriSalus Life Sciences (TLSI) - The Globe and Mail
Structure Therapeutics Reports Weight Loss Success in Obesity Drug Trial - HarianBasis.co
Universal Beteiligungs und Servicegesellschaft mbH Buys 67,338 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Upgraded by Canaccord Genuity Group to Strong-Buy Rating - MarketBeat
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Structure Therapeutics (GPCR) Leerink Global Healthcare Conference 2025 Summary - Quartr
Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific Sessions - The Manila Times
Five obesity and diabetes studies from Structure Therapeutics head to ADA - Stock Titan
Assessing Structure Therapeutics (GPCR) Valuation After Recent Share Price Pullback - Sahm
Peregrine Capital Management LLC Buys Shares of 84,324 Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
[Form 4] Structure Therapeutics Inc. Insider Trading Activity - Stock Titan
[ARS] Structure Therapeutics Inc. SEC Filing - Stock Titan
Structure Therapeutics (NASDAQ: GPCR) details 2026 virtual shareholder meeting - Stock Titan
Structure Therapeutics (GPCR) COO & GC Matthew Lang files initial Form 3 - Stock Titan
Analysts’ Top Healthcare Picks: Perspective Therapeutics (CATX), Nektar Therapeutics (NKTR) - The Globe and Mail
Discipline and Rules-Based Execution in GPCR Response - Stock Traders Daily
Is Structure Therapeutics (GPCR) Building a Legal-Led Edge in Its Obesity and Metabolic Pipeline Strategy? - Sahm
Finanzdaten der Structure Therapeutics Inc Adr-Aktie (GPCR)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.98%
1.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):